Kornfeld Steven sold FBRX
August 27, 2026 · Form 4 insider transaction
Kornfeld Steven sold 3,960 shares of Forte Biosciences Inc, a transaction worth N/A. The trade was recorded as u and disclosed on an SEC Form 4, filed 0 days after the transaction.
Footnotes
Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for $77.00 per share ("Merger Consideration"), net to the seller in cash, without interest, subject to any required withholding tax. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent.